Eli Lilly and Company Provides Statement in Response to Sanofi U.S. Lawsuit
INDIANAPOLIS, Jan. 31, 2014
INDIANAPOLIS, Jan.31, 2014 /PRNewswire/ --Eli Lilly and Company (NYSE: LLY)
has provided the following statement regarding a lawsuit filed by Sanofi in
the United States District Court for the District of Delaware alleging patent
infringement with respect to LY2963016, a new insulin glargine product for
which Lilly is currently seeking approval from the U.S. Food and Drug
"Lilly respects the intellectual property of others and does not believe the
application for approval of its new insulin glargine product infringes any
valid claim of the asserted patents," said Doug Norman, vice president and
general patent counsel, Eli Lilly and Company.
Lilly, and its alliance partner Boehringer Ingelheim, recently announced the
FDA had accepted the filing of the New Drug Application (NDA) for LY2963016,
an investigational basal (long-acting) insulin.
LY2963016 is a new insulin glargine product developed for the treatment of
patients with type 1 and type 2 diabetes. The NDA was filed through the
505(b)(2) regulatory pathway, which allows the FDA to reference previous
findings of safety and efficacy for an already-approved product (insulin
glargine) in addition to the studies of LY2963016.
Under the Hatch-Waxman act, the initiation of the lawsuit automatically
invokes a stay on FDA approval of the product for a period of 30 months, or
until a court finds in favor of Lilly, whichever is sooner. It is too early
to speculate whether a resolution would occur before the end of the 30-month
litigation stay in mid-2016.
In July 2013, the companies announced the marketing authorization application
(MAA) for LY2963016 was accepted for review by the European Medicines Agency
Approximately 24.4 million Americans and an estimated 382 million people
worldwide have type 1 or type 2 diabetes. Type 2 diabetes is the most common
type, accounting for an estimated 85 to 95 percent of all diabetes cases.
Diabetes is a chronic condition that occurs when the body either does not
properly produce, or use, the hormone insulin. Diabetes was estimated to cost
the U.S. $263 billion in 2013.^1
About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make
life better for people around the world. We were founded more than a century
ago by a man committed to creating high-quality medicines that meet real
needs, and today we remain true to that mission in all our work. Across the
globe, Lilly employees work to discover and bring life-changing medicines to
those who need them, improve the understanding and management of disease, and
give back to communities through philanthropy and volunteerism. To learn more
about Lilly, please visit us at www.lilly.comand
This press release contains forward-looking statements about LY2963016 for the
treatment of diabetes. It reflects Lilly's current beliefs; however, as with
any such undertaking, there are substantial risks and uncertainties in the
process of drug development and commercialization. There is no guarantee that
future study results and patient experience will be consistent with study
findings to date or that LY2963016 will receive regulatory approval or prove
to be commercially successful. For further discussion of these and other risks
and uncertainties, please see Lilly's latest Forms 10-Q and 10-K filed with
the U.S. Securities and Exchange Commission. Lilly undertakes no duty to
update forward-looking statements.
1. International Diabetes Federation. IDF Diabetes Atlas, 6th edn. Brussels,
Belgium: International Diabetes Federation, 2013.
http://www.idf.org/diabetesatlas. Accessed on December 18, 2013.
Refer to: Tamara Hull, +1-317-651-9116, email@example.com
SOURCE Eli Lilly and Company
Press spacebar to pause and continue. Press esc to stop.